Testicular relapse of leukemia and lymphoma is a well-recognized phenomenon, with testicular relapse of lymphoma being more common in the adult population and leukemia relapse being more common in the pediatric population. With the advent of F-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the evaluation of lymphoma it is possible to evaluate testicular uptake of FDG and to detect primary testicular lymphoma or testicular relapse on the FDG-PET examination. Testicular relapse of non-Hodgkin lymphoma (NHL) detected on FDG-PET has been reported previously. We report an additional case in which there was testicular activity at presentation, a response to therapy (orchiectomy not performed) and then testicular relapse followed by orchiectomy. We review the literature with regard to testicular recurrence and testicular uptake of FDG-PET. There have been studies that have examined normal standardized uptake value maximum (SUVmax) values in the testicle, with normal values ranging from 2.81 (30-39 years) to 2.18 (80-89 years), depending upon age. However, it should be noted that there could be considerable variability in SUVmax values depending upon the units used (e.g. normalized to lean body mass vs. body weight) and depending upon examination variables such as dietary conditions, muscle uptake or extravasation of FDG. Elevated activity or lateralizing activity should be viewed with suspicion, with etiologies including primary testicular tumor, primary or secondary testicular lymphoma and metastatic disease with other etiologies less likely.
CASE REPORT
The patient was a 50-year-old male at presentation when he began experiencing low back pain, weight loss, abdominal pain, early satiety and dysuria. A computed tomography (CT) scan was performed and demonstrated retroperitoneal and abdominal adenopathy (Fig 1) . A positron emission tomography-computed tomography (PET/CT) performed the following day demonstrated the same findings with posterior mediastinal adenopathy, abdominal adenopathy and right testicular involvement with a SUVmax of 9.6 (Fig 2) . Biopsy of a retroperitoneal lymph node at this time revealed nonHodgkin's lymphoma, large cell type. He then underwent chemotherapy with Rituxan followed by Etopiside, Vincristine, Adriamycin, Prednisone and Cyclophosphamide (EPOCH), followed by additional cycles of Rituxan/EPOCH. A followup PET/CT performed 3 months after presentation demonstrated positive response of the adenopathy to therapy CASE REPORT and testicular uptake that was more symmetric, with SUVmax 5.3 on the right and SUVmax 4.2 on the left (Fig 3) . PET/CT performed 7 months after presentation demonstrated some mild asymmetric activity in the testicles with SUVmax on the right of 4.4 and SUVmax on the left of 3.7 (Fig 4) . No other active disease by PET/CT was reported. PET/CT performed 11 months after presentation demonstrated recurrent isolated uptake in the right testicle with SUVmax of 12.4 (Fig 5) . This was followed by an ultrasound examination (Fig 6 and Fig 7) and orchiectomy which showed diffuse large B-cell lymphoma infiltrating the testicle and staining positive for CD20, a B-cell antigen and B-cell tumor antigen against which Rituxan is directed (Fig 8 and Fig 9) . Testicular lymphoma can be either primary or secondary. Lymphoma (primary and secondary) of the testis accounts for 5% of all testicular malignancies and 1% of all lymphomas. It is the most common testicular malignancy in patients older than 60 years of age. (1).
In one study examining 388 male patients with nonHodgkin lymphoma from 1975 to 1988, 8 patients (2%) had testicular involvement. 2 cases were considered to be primary, 4 systemic disease and 2 as secondary or late complications. 203 autopsies from the same study examining 124 male patients found 11 cases (8.9%) with testicular involvement, with only 2 of these known prior to autopsy (2).
An early study examining autopsy findings in leukemia and lymphoma found testicular involvement in 64.3% of 140 male patients with acute leukemia, 22.4% of 76 male patients with chronic leukemia and 18.6% of patients with lymphosarcoma (NHL). None of the 44 patients with Hodgkin's disease had testicular involvement (3).
In primary testicular lymphoma involvement of extranodal sites such as the contralateral testis, CNS, skin and Waldeyer's ring is common and there is a high incidence of relapse, with the CNS sometimes being the only site of recurrence (1). Whether the lymphoma is secondary or primary there is some resistance to treatment related to the blood-testis barrier. This normally functions to protect developing germ cells against harmful agents and immunological influences, although this is problematic in the treatment of testicular tumors and testicular lymphoma (4). In our case the involvement was likely secondary and was likely present at presentation with an initial response to therapy and eventual relapse within the testicle.
The metabolic activity within the testicles is usually somewhat higher than background or blood pool activity. In a study examining 406 testes in 203 patients undergoing PET/CT for other indications (117 lung cancer, 16 head and neck, 12 colorectal, 6 gastric, 5 melanoma, 4 pancreas, 3 esophagus, 5 other) the SUVmax was 2.44, with the value ranging from 2.81 (30-39 years) to 2.18 (80-89 years) (5). It should be noted that there could be significant variability in SUVmax values within a given institution and between institution depending upon equipment, the units used for SUVmax values (e.g. normalized to lean body mass or body weight), dietary factors, muscle uptake, blood glucose levels or extravasation of FDG. Any significant elevation in the SUVmax value or asymmetric activity should be viewed with suspicion. One should be familiar with the normal range for testicular activity using their institutional protocols and equipment since values may vary.
NHL testicular lymphoma is FDG avid and can be detected on PET or PET/CT being performed for staging or follow-up of non-Hodgkin lymphoma. An elevated SUVmax value or asymmetric activity should be viewed with suspicion, although one should be cognizant of pitfalls with relying on SUVmax values alone. The testis is an immunologically privileged site and the blood-testis barrier interferes with the delivery of chemotherapeutic agents, making the testis a potential site for relapse. 
